-

12:38:21 PM

OPTHF Stock News

OPTHF - Optimi Health Corp

09/14/23 2:59 PM

OTC : OPTHF

clinical trial

Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased to see the positive and encouraging outcomes from the MAPS Phase 3 MDMA-Assisted Therapy (MDMA-AT)

RHEA-AI

neutral

09/07/23 7:30 AM

OTC : OPTHF

Optimi Health Granted Amendment to Dealer's Licence by Health Canada to Supply Special Access Program

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, proudly announced today that Health Canada has approved an amendment to the Company’s Dealer's Licence. The

RHEA-AI

neutral

09/05/23 7:30 AM

OTC : OPTHF

Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt Financing

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“ Optimi Health ” or the “ Company ”), a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and

RHEA-AI

neutral

08/10/23 7:30 AM

OTC : OPTHF

Optimi Health Announces CAD $3,000,000 Senior Debt Financing

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian drug research and formulation company licensed by Health Canada to

RHEA-AI

neutral

08/01/23 7:30 AM

OTC : OPTHF

Optimi Completes Proprietary Natural Psilocybin Extraction Process and Files U.S. Provisional Patent

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes and in controlled

RHEA-AI

neutral

07/27/23 9:20 AM

OTC : OPTHF

Optimi Health Announces Receipt of Purported Termination Notice

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”) has received a termination notice and demand for payment pursuant to a definitive supply agreement (the “Supply Agreement”) with a private entity

RHEA-AI

neutral

06/15/23 9:40 AM

OTC : OPTHF

Optimi Health To Supply MDMA For Therapist Experiential Training Program at Numinus, Supported by MAPS

Optimi Health Corp. ( CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an

RHEA-AI

positive

05/17/23 8:15 AM

OTC : OPTHF

Optimi Health Completes Harvest Of Psilocybe Cubensis For Delivery To The Australian Medical Market

Optimi Health Corp. ( CSE: OPTI)

RHEA-AI

neutral

05/10/23 8:45 AM

OTC : OPTHF

Optimi Health Granted Natural Health Product Site Licence By Health Canada

Optimi Health Corp. ( CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic

RHEA-AI

neutral

05/04/23 9:00 AM

OTC : OPTHF

clinical trial

Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical Research and Development

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“ Optimi ” or the “ Company ”), today announced that it has entered into a CAD$1.2

RHEA-AI

neutral

1 2 3 4 5 6 7 Next